ERBB2 and bone metastasis: In the oncogene-positive IO group, a total of six patients reached the EFS endpoint, including one MET-amplified patient (P15) who did not undergo surgery, two patients harbouring RET-KIF5B with postoperative ilium bone metastasis (P16) and mediastinal lymph node metastasis (P17), one EGFR L858R-mutant patient (P2) with mediastinal lymph node metastasis, one ERBB2-amplified patient (P5) with liver metastasis, and one KRAS G12C-mutant patient with brain metastasis (P9).